Skin and ophthalmic complications of chloroquine and hydroxychloroquine in patients with rheumatoid arthritis and systemic lupus erythematous

References

• Saag, K. G.; Teng, G. G.; Patkar, N. M.; Anuntiyo, J.; Finney, C.; Curtis, J. R.; Paulus, H. E.; Mudano, A.; Pisu, M.; Elkins‐Melton, M., et al. American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthritis Care Res: Official J. Am. College Rheumatol. 2008, 59(6), 762–784.
   PubMed Web of Science ®Google Scholar
• Fathi, F.; Atapour, A.; Eskandari, N.; Keyhanmehr, N.; Hafezi, H.; Mohammadi, S.; Motedayyen, H. Regulatory T-Cells and Their Impacts on Cytokine Profile of End-Stage Renal Disease Patients Suffering from Systemic Lupus Erythematosus. Intern J. Immunopath. Pharmacol. 2019, 33, 2058738419863238. DOI: 10.1177/2058738419863238.
   Web of Science ®Google Scholar
• Fathi, F.; Sadeghi, E.; Lotfi, N.; Hafezi, H.; Ahmadi, M.; Mozafarpoor, S.; Motedayyen, H. Effects of the Programmed Cell Death 1 (PDCD1) Polymorphisms in Susceptibility to Systemic Lupus Erythematosus. Int. J. Immunogenet. 2020, 47(1), 57–64. DOI: 10.1111/iji.12456.
   PubMed Web of Science ®Google Scholar
• Zamani, B.; Moradi Hasan‐Abad, A.; Piroozmand, A.; Dehghani, M.; Arfaatabar, M.; Motedayyen, H. Immunogenicity and Safety of the BBIBP‐CorV Vaccine in Patients with Autoimmune Inflammatory Rheumatic Diseases Undergoing Immunosuppressive Therapy in a Monocentric Cohort. Immun. Inflamm. Dis. 2023, 11(5), e858. DOI: 10.1002/iid3.858.
   PubMed Web of Science ®Google Scholar
• Sun, L.; Akiyama, K.; Zhang, H.; Yamaza, T.; Hou, Y.; Zhao, S.; Xu, T.; Le, A.; Shi, S. Mesenchymal Stem Cell Transplantation Reverses Multiorgan Dysfunction in Systemic Lupus Erythematosus Mice and Humans. Stem Cells. 2009, 27(6), 1421–1432.
   PubMed Web of Science ®Google Scholar
• Schoels, M.; Aletaha, D.; Smolen, J. S.; Bijlsma, J. W.; Burmester, G.; Breedveld, F. C.; Cutolo, M.; Combe, B.; Dougados, M.; Emery, P. Follow-Up Standards and Treatment Targets in Rheumatoid Arthritis: Results of a Questionnaire at the EULAR 2008. Ann. Rheumatic Dis. 2010, 69(3), 575–578.
   PubMed Web of Science ®Google Scholar
• Cukras, C.; Huynh, N.; Vitale, S.; Wong, W. T.; Ferris, F. L., III; Sieving, P. A. Subjective and Objective Screening Tests for Hydroxychloroquine Toxicity. Ophthalmol. 2015, 122(2), 356–366. DOI: 10.1016/j.ophtha.2014.07.056.
   PubMed Web of Science ®Google Scholar
• Gorter, S.; Bijlsma, J. W.; Cutolo, M.; Gomez-Reino, J.; Kouloumas, M.; Smolen, J. S. Current Evidence for the Management of Rheumatoid Arthritis with Glucocorticoids: A Systematic Literature Review Informing the EULAR Recommendations for the Management of Rheumatoid Arthritis. Ann. Rheumatic Dis. 2010, 69(6), 1010–1014.
   PubMed Web of Science ®Google Scholar
• Melles, R. B.; Marmor, M. F. Pericentral Retinopathy and Racial Differences in Hydroxychloroquine Toxicity. Ophthalmol. 2015, 122(1), 110–116. DOI: 10.1016/j.ophtha.2014.07.018.
   PubMed Web of Science ®Google Scholar
• Liu, Q.; Tang, Z.; Surdenikova, L.; Kim, S.; Patel, K. N.; Kim, A.; Ru, F.; Guan, Y.; Weng, H.-J.; Geng, Y. Sensory Neuron-Specific GPCR Mrgprs Are Itch Receptors Mediating Chloroquine-Induced Pruritus. Cell. 2009, 139(7), 1353–1365.
   PubMed Web of Science ®Google Scholar
• Iselin, K.; Marti, P.; Pless, M. Hydroxychloroquine-Induced Retinal Toxicity. Klinische Monatsblätter für Augenheilkunde. 2016, 233(4), 514–516. DOI: 10.1055/s-0042-102615.
   PubMed Web of Science ®Google Scholar
• Hafström, I.; Albertsson, K.; Boonen, A.; Van Der Heijde, D.; Landewe, R.; Svensson, B. Remission Achieved After 2 Years Treatment with Low-Dose Prednisolone in Addition to Disease-Modifying Anti-Rheumatic Drugs in Early Rheumatoid Arthritis Is Associated with Reduced Joint Destruction Still Present After 4 Years: An Open 2-Year Continuation Study. Ann. Rheumatic Dis. 2009, 68(4), 508–513.
   PubMed Web of Science ®Google Scholar
• Navajas, E. V.; Krema, H.; Hammoudi, D. S.; Lipton, J. H.; Simpson, E. R.; Boyd, S. Retinal Toxicity of High-Dose Hydroxychloroquine in Patients with Chronic Graft-Versus-Host Disease. Can. J. Ophthalmol. 2015, 50(6), 442–450.
   PubMed Web of Science ®Google Scholar
• Sabitha, P.; Adhikari, M. P.; Kuruvilla, M. Hyperpigmentation of the Skin Following Chloroquine Treatment–Case Series Report. 2005.
   Google Scholar
• Yusuf, I.; Sharma, S.; Luqmani, R.; Downes, S. Hydroxychloroquine Retinopathy. Eye. 2017, 31(6), 828–845. DOI: 10.1038/eye.2016.298.
   PubMed Web of Science ®Google Scholar
• Jaumouillé, S.; Espargillière, D.; Mouriaux, F.; Mortemousque, B. Clinical Evaluation of the New Screening Procedures for Hydroxychloroquine Retinopathy, According to the American Academy of Ophthalmology Guidelines. Prospective Study of 184 Patients. J. Francais D’ophtalmologie. 2015, 38(5), 377–387. DOI: 10.1016/j.jfo.2015.01.005.
   PubMed Web of Science ®Google Scholar
• Melles, R. B.; Marmor, M. F. The Risk of Toxic Retinopathy in Patients on Long-Term Hydroxychloroquine Therapy. JAMA Ophthalmol. 2014, 132(12), 1453–1460. DOI: 10.1001/jamaophthalmol.2014.3459.
   PubMed Web of Science ®Google Scholar
• Tangtavorn, N.; Yospaiboon, Y.; Ratanapakorn, T.; Sinawat, S.; Sanguansak, T.; Bhoomibunchoo, C. Incidence of and Risk Factors for Chloroquine and Hydroxychloroquine Retinopathy in Thai Rheumatologic Patients. Clin. Ophthalmol. (Auckland, NZ). 2016, 10, 2179.
   PubMedGoogle Scholar
• Eo, D.-R.; Lee, M. G.; Ham, D.-I.; Kang, S. W.; Lee, J.; Cha, H. S.; Koh, E.; Kim, S. J. Frequency and Clinical Characteristics of Hydroxychloroquine Retinopathy in Korean Patients with Rheumatologic Diseases. J. Korean. Med. Sci. 2017, 32(3), 522–527. DOI: 10.3346/jkms.2017.32.3.522.
   PubMed Web of Science ®Google Scholar
• Gladman, D. D.; Urowitz, M. B.; Goldsmith, C. H.; Fortin, P.; Ginzler, E.; Gordon, C.; Hanly, J. G.; Isenberg, D. A.; Kalunian, K.; Nived, O. The Reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in Patients with Systemic Lupus Erythematosus. Arthritis Rheum: Official J. Am. College Rheumatol. 1997, 40(5), 809–813.
   PubMedGoogle Scholar
• Cohen, S.; Emery, P. The American College of Rheumatology/European League Against Rheumatism Criteria for the Classification of Rheumatoid Arthritis: A Game Changer; Annals of the Rheumatic Diseases: BMJ Publishing Group Ltd, 2010; pp. 1575–1576. DOI:10.1136/ard.2010.138446.
   Google Scholar
• Britsemmer, K.; Ursum, J.; Gerritsen, M.; van Tuyl, L.; van Schaardenburg, D. Validation of the 2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis: Slight Improvement Over the 1987 ACR Criteria. Ann. Rheumatic Dis. 2011, 70(8), 1468–1470. DOI: 10.1136/ard.2010.148619.
   PubMed Web of Science ®Google Scholar
• Jorge, A.; Ung, C.; Young, L. H.; Melles, R. B.; Choi, H. K. Hydroxychloroquine Retinopathy—Implications of Research Advances for Rheumatology Care. Nat Review Rheumatol. 2018, 14(12), 693–703. DOI: 10.1038/s41584-018-0111-8.
   PubMed Web of Science ®Google Scholar
• Lenfant, T.; Salah, S.; Leroux, G.; Bousquet, E.; Le Guern, V.; Chasset, F.; Francès, C.; Morel, N.; Chezel, J.; Papo, T. Risk Factors for Hydroxychloroquine Retinopathy in Systemic Lupus Erythematosus: A Case–Control Study with Hydroxychloroquine Blood-Level Analysis. Rheumatology. 2020, 59(12), 3807–3816.
   PubMed Web of Science ®Google Scholar
• Petri, M.; Elkhalifa, M.; Li, J.; Magder, L. S.; Goldman, D. W. Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. Arthritis Rheumatol. 2020, 72(3), 448–453. DOI: 10.1002/art.41121
   PubMed Web of Science ®Google Scholar
• Marmor, M. F. Retinopathy from Hydroxychloroquine Is Not Related to Lupus or Rheumatoid Arthritis. Doc. Ophthalmol. 2018, 136(1), 93–94. DOI: 10.1007/s10633-018-9623-4.
   PubMed Web of Science ®Google Scholar
• Wolfe, F.; Marmor, M. F. Rates and Predictors of Hydroxychloroquine Retinal Toxicity in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus. Arthritis Care Res. 2010, 62(6), 775–784. DOI: 10.1002/acr.20133.
   PubMed Web of Science ®Google Scholar
• Fanouriakis, A.; Kostopoulou, M.; Alunno, A.; Aringer, M.; Bajema, I.; Boletis, J. N.; Cervera, R.; Doria, A.; Gordon, C.; Govoni, M. 2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus. Ann. Rheumatic Dis. 2019, 78(6), 736–745.
   PubMed Web of Science ®Google Scholar
• Easterbrook, M., editor. The Ocular Safety of Hydroxychloroquine. Seminars in Arthritis and Rheumatism; WB Saunders: Elsevier, 1993; p 62–67. DOI:10.1016/S0049-0172(10)80009-5.
   Google Scholar
• Sardana, K.; Sinha, S.; Sachdeva, S. Hydroxychloroquine in Dermatology and Beyond: Recent Update. Indian Dermatology Online J. 2020, 11(3), 453. DOI: 10.4103/idoj.IDOJ_280_20
   PubMedGoogle Scholar
• Jallouli, M.; Francès, C.; Piette, J.-C.; Moguelet, P.; Factor, C.; Zahr, N. Hydroxychloroquine-Induced Pigmentation in Patients with Systemic Lupus Erythematosus: A Case-Control Study. JAMA Dermatol. 2013, 149(8), 935–940.
   PubMed Web of Science ®Google Scholar
• Coulombe, J.; Boccara, O. Hydroxychloroquine-Related Skin Discoloration. CMAJ. 2017, 189(5), E212–E. DOI: 10.1503/cmaj.150622.
   PubMed Web of Science ®Google Scholar
• Ricardo, J. W.; Chikeka, I.; Silvers, D. N.; Lipner, S. R. Longitudinal Melanonychia and Skin Hyperpigmentation Associated with Hydroxychloroquine Therapy. JAAD Case Rep. 2021, 7, 23. DOI: 10.1016/j.jdcr.2020.10.030.
   PubMedGoogle Scholar